Tablet core: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, colloidal
silicon dioxide, sodium stearyl fumarate. Film-coat:hydroxy propyl methylcellulose (E464),
titanium dioxide (E171), polyethylene glycol (E1521), iron oxide red (E172).
Tablet core: copovidone, sorbitan laureate, silica, colloidal anhydrous, calcium hydrogen
phosphate, anhydrous, sodium stearyl fumarate. Film-coat: hypromellose (E464), titanium dioxide
(E171), macrogol, hydroxypropyl cellulose (E463), talc (E553b), silica, colloidal anhydrous
(E551), polysorbate 80 (E433).
For information regarding other allergen/ingredients, please contact Medical Information at
contact our Medical Information team on
Each Nirmatrelvir 150 mg film-coated tablet contains 176 mg of lactose. Patients
with rare hereditary problems of galactose intolerance, total lactase deficiency or
glucose-galactose malabsorption should not take this medicine.
We cannot guarantee that minute amounts of substances are not contained in raw materials obtained
from our suppliers. To ensure we have a consistent and reliable supply of medications, we must use
a network of suppliers and manufacturing sites globally for both active and inactive
Nirmatrelvir and ritonavir each contain less than 1 mmol sodium (23 mg) per dose, that is to say
essentially ‘sodium free’.
Ritonavir is administered with PF-07321332 as a pharmacokinetic enhancer resulting in higher systemic concentrations of PF-07321332.
Ritonavir is not active against the SARS-CoV-2 3CL protease. Ritonavir inhibits the CYP3A-mediated metabolism of PF-07321332, thereby providing increased plasma concentrations of PF-07321332.
In healthy participants, the mean half-life of a single dose of 150 mg PF‑07321332 administered alone was approximately 2 hours compared to 7.5 hours after administration of a single dose of 250 mg/100 mg dose of PF-07321332/ritonavir thereby supporting a twice‑daily administration regimen.
View Paxlovid™ (Nirmatrelvir (PF-07321332))/Ritonavir)
Summary of Product Characteristics